Clinical trials: Age Related Maculopathy
Macular Degeneration, Age Related, Maculopathy, Age Related
Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration
An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images.
- Trial name
- NCT05593913
- Where
- Taiwan
- Volunteers
- 986 people
- Sponsor
- Acer Medical Inc.
Glaucoma, Age Related Macular Degeneration
Assessment of Visual Function With a Portable Brain-computer Interface
1. The purpose of this study is to evaluate the nGoggle's accuracy and repeatability in detecting visual function loss. In addition, the ability to stage glaucomatous damage and investigate the relationship between nGoggle…
- Conditions
- Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
- Trial name
- NCT03760055
- Testing
- nGoggle
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NGoggle
Wet Age-related Macular Degeneration, Age-related Macular Degeneration
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
The objective of this study is to confirm the safety and to establish the effectiveness of low voltage external beam radiosurgery using the IRay System for the treatment of subjects with recurrent leakage secondary to neovascular…
- Conditions
- Wet Age-related Macular Degeneration, Age-related Macular Degeneration, AMD, Wet AMD
- Trial name
- NCT01339949
- Testing
- IRay
- Where
- 3 sites in Italy, United Kingdom
- Sponsor
- Oraya Therapeutics, Inc.
Exudative Macular Degeneration
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.
- Trial name
- NCT01617148
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rishi Singh
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
The study will evaluate the efficacy and safety of two different dosing regimens of ranibizumab (0.5 mg on BCVA by 1+PRN vs 3+PRN) in Chinese patients with wet AMD.
- Trial name
- ARTIS (NCT02810808)
- Testing
- 1+PRN, 3+PRN, Ranibizumab
- Where
- 5 sites in China
- Volunteers
- 115 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-Related Macular Degeneration
Virtual Reality Based Vision Test in Patients With AMD
To assess the usability, tolerability, and repeatability of the set of VR headset-based tasks.
- Trial name
- GA-001 (NCT06241625)
- Testing
- Virtual Reality (VR) Contrast Function Test
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Augenklinik Zurich West
Neovascular Age-related Macular Degeneration (nAMD)
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
- Trial name
- NOVA-1 (NCT05769153)
- Testing
- AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant
- Where
- 42 sites in United States
- Volunteers
- 139 people
- Sponsor
- Alcon Research
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular…
- Trial name
- NCT07695207
- Testing
- SMZ1
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- SANGMYUNG innovation
Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Observation of the Natural Course of Age-related Macular Degeneration
This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a…
- Trial name
- NCT05418231
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Age-related Macular Degeneration
Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)
Age-related macular degeneration is a chronic degenerative retinal disease, which can lead to a progressive loss of visual acuity without affecting peripheral vision.
- Trial name
- FATTY (NCT04278300)
- Testing
- blood sampling, faecal sampling (optional)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Macular Degeneration
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
- Trial name
- XPLORE (NCT03805100)
- Testing
- Ranibizumab
- Where
- 102 sites in United States, Bulgaria and 13 more
- Volunteers
- 582 people
- Sponsor
- Xbrane Biopharma AB
Neovascular Age-related Macular Degeneration
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.
- Trial name
- Mylight (NCT04864834)
- Testing
- SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL)
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 485 people
- Sponsor
- Sandoz
Age-related Macular Degeneration
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD).
- Trial name
- SALUTE (NCT01148511)
- Testing
- Ranibizumab 0.5 mg
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy, Age-Related Macular Degeneration
Oral Postbiotics in Patients With Macular Atrophy
A pilot study to evaluate the safety and efficacy of oral therapy with Postbiotics in patients with geographic atrophy secondary to age-related macular degeneration, myopia, or angioid streaks.
- Trial name
- REVERS-GA (NCT05391074)
- Testing
- postbiotics (IGENH35.3A), vitamins (AREDS formulation and recommended daily dose)
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Institut de la Macula y la Retina
Wet Macular Degeneration
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in…
- Trial name
- PERSEUS-IT (NCT02289924)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Italy
- Volunteers
- 912 people
- Sponsor
- Bayer
Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs) and the safety…
- Trial name
- NCT07662096
- Testing
- ARO-033
- Where
- New Zealand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Age-Related Macular Degeneration
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
- Trial name
- NCT00148551
- Testing
- Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Retinal Trials Group
Dry Age Related Macular Degeneration
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry AMD To evaluate the safety of the surgical procedures when used to implant MA09-hRPE cells To assess the number of hRPE cells to…
- Trial name
- NCT01674829
- Testing
- MA09-hRPE
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHABiotech CO., Ltd
Macular Degeneration, Age-related Maculopathies
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD).
- Conditions
- Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy, Maculopathies,Age-related
- Trial name
- AMD (NCT01494805)
- Testing
- rAAV.sFlt-1, Control (ranibizumab alone)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Lions Eye Institute, Perth, Western Australia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.